3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
222
Liver Neoplasms
68
Neoplasms
18
Pancreatic Neoplasms
16
Neoplasm Metastasis
14
Colorectal Neoplasms
12
Rectal Neoplasms
8
Stomach Neoplasms
7
Colonic Neoplasms
7
Carcinoma, Renal Cell
6
Carcinoma
6
Liver Diseases
5
Gallbladder Neoplasms
5
Breast Neoplasms
5
Digestive System Neoplasms
4
Bile Duct Neoplasms
4
Prostatic Neoplasms
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Adenocarcinoma
3
Neoplasms, Glandular and Epithelial
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Multiple Myeloma
2
Melanoma
2
Hepatoblastoma
2
Hepatitis C
2
Hepatitis B
2
Hematologic Neoplasms
2
Glioblastoma
2
Interventions
Sorafenib
1
Irinotecan
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vaccinia
×
Sorafenib
×
Gastrointestinal
×
Clear all
NCT02562755
2020-12-16
PHOCUS
SillaJen, Inc.
Phase 3
Completed
459 enrolled
12 charts